fbpx

AbbVie’s stock is down 3% after missing on revenue in the first quarter of 2022

An earlier version of this report incorrectly listed Rinvoq’s revenue. The drug generated $465 million in revenue in the first quarter of 2022.

Shares of AbbVie Inc.
ABBV,
-0.83%

were down 3.4% in premarket trading on Friday after the company missed on revenue in the first quarter of the year. AbbVie had earnings of $4.5 billion, or $2.51 per share, in the first quarter of 2022, up from $3.5 billion, or $1.99 per share, in the same quarter of 2021. Adjusted earnings per share were $3.16. The FactSet consensus was $3.14. The company said it had revenue of $13.5 billion for the quarter, up from $13.0 billion, against a FactSet consensus of $13.6 billion. Top-performing products included eczema treatment Rinvoq (up 53.6% to $465 million), its aesthetics franchise, which includes Botox Cosmetic and Juvederm (up 20.% to $1.3 billion), and psoriasis treatment Skyrizi (up 63.7% to $940 million). However, sales of Humira, its top-selling drug, fell 2.7% to $4.7 billion, as did sales of lymphoma treatment Imbruvica, which came in at $1.1 billion. AbbVie updated its guidance for adjusted EPS for 2022, saying it now expects $13.92 to $14.12 instead of $14.00 – $14.20. The company’s stock has gained 15.4% this year, while the broader S&P 500
SPX,
+2.47%

is down 10.0%.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

^N225 
$28,162.83  $120.20  0.42%  
SGHIF 
$1.08  $0.0000  0.00%  
^HSIL 
$32.46  $2.80  9.44%  
SZNTF 
$0.148  $0.0000  0.00%  
KOSPI.KS 
$2,408.27  $29.59  1.21%  
AUS.NZ 
$3.13  $0.004  0.13%  
^NSEI 
₹ 18,562.75  ₹ 50.00  0.27%  
FCNBCA.FGI 
$7,658.02  $92.96  1.20%  
EURUSD=X 
$1.04  $0.0019  0.19%  
GBPUSD=X 
$1.20  $0.007  0.58%  
JPY=X 
$138.86  $0.243  0.17%  
^GSPC 
$3,992.42  $33.70  0.84%  
NDAQ 
$66.88  $0.27  0.40%  
^DJI 
$34,092.50  $254.53  0.74%